福坦替尼治疗温抗体型自身免疫性溶血性贫血:2期、多中心、开放标签研究
这项2期多中心开放标签研究评估福坦替尼150 mg每日两次口服治疗既往至少一种治疗失败的温抗体型自身免疫性溶血性贫血成人患者,主要终点为第24周血红蛋白>10 g/dL且较基线升高≥2 g/dL且未接受 rescure 治疗或输血,24例中11例(46%)达到主要终点,最常见不良事件为腹泻(42%)、乏力(42%)、高血压(27%)、头晕(27%)和失眠(23%)。
要点
- 24例可评估患者中11例(46%)达到主要终点。
- 中位血红蛋白在第2周即出现升高并持续维持。
- 常见不良事件为腹泻(42%)、乏力(42%)、高血压(27%)、头晕(27%)和失眠(23%)。
核心结论
- 福坦替尼可能成为温抗体型自身免疫性溶血性贫血有前景的治疗选择。
- 一项随机、双盲、3期研究即将完成。
研究设计与样本
- 2期、多中心、开放标签研究,纳入成人温抗体型自身免疫性溶血性贫血且存在活动性溶血(血红蛋白<10 g/dL)、既往至少一种治疗失败的患者。
- 福坦替尼150 mg每日两次口服,可与食物同服或不同服。
- 每2周进行血红蛋白水平和安全性评估。
主要发现
- 24例患者中11例(46%)达到主要终点(第24周血红蛋白>10 g/dL且较基线升高≥2 g/dL,未接受 rescue 治疗或红细胞输注)。
- 中位血红蛋白在第2周即出现升高并随时间持续。
- 中位乳酸脱氢酶水平和网织红细胞计数总体随时间下降,中位结合珠蛋白水平变化不大。
- 最常见不良事件为腹泻(42%)、乏力(42%)、高血压(27%)、头晕(27%)和失眠(23%)。
- 不良事件可控,与福坦替尼在超过3900例多种疾病患者(类风湿关节炎、B细胞淋巴瘤、COVID-19和ITP)中的安全性数据库一致,未发现新的安全性信号。
关键数值与推荐
- 主要终点:第24周血红蛋白>10 g/dL且较基线升高≥2 g/dL,未接受 rescue 治疗或红细胞输注。
- 福坦替尼给药方案:150 mg每日两次口服,可与食物同服或不同服。
临床怎么用
- 福坦替尼可能成为温抗体型自身免疫性溶血性贫血有前景的治疗选择(作者结论)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with relapsed warm antibody autoimmune hemolytic anemia (wAIHA) have limited treatment options. Fostamatinib is a potent, orally administered spleen tyrosine kinase inhibitor approved in the United States and Europe for the treatment of adults with chronic immune thrombocytopenia (ITP). This phase 2 study evaluated the response to fostamatinib, administered at 150 mg BID orally with or without food in adults with wAIHA and active hemolysis with hemoglobin (Hgb) <10 g/dL who had failed at least one prior treatment. Hemoglobin levels and safety assessments were performed at visits every 2 weeks. The primary endpoint was Hgb >10 g/dL with an increase of ≥2 g/dL from baseline by week 24 without rescue therapy or red blood cell transfusion. Eleven of 24 (46%) patients achieved the primary endpoint. Increases in median Hgb were detected at week 2 and sustained over time. Median lactate dehydrogenase levels and reticulocyte counts generally declined over time with little change in median haptoglobin levels. The most common adverse events (AEs) were diarrhea (42%), fatigue (42%), hypertension (27%), dizziness (27%), and insomnia (23%). AEs were manageable and consistent with the fostamatinib safety database of over 3900 patients across multiple diseases (rheumatoid arthritis, B-cell lymphoma, COVID-19, and ITP). No new safety signals were detected. Fostamatinib may be a promising therapeutic option for wAIHA. A randomized, double-blind, phase 3 study is nearing completion.
引用
- Kuter DJ, Rogers KA, Boxer MA, et al. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study. Am J Hematol. 2022. PMID: 35179251. doi:10.1002/ajh.26508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。